Rivals In India Begin Shadow Fight As Researchers Find Possible Link Between Sanofi-Aventis' Lantus And Cancer
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - As Sanofi-Aventis engages in fire fighting to counter claims made by the European Association for the Study of Diabetes that there is a link between Sanofi's Lantus (insulin glargine) and an increased risk of cancer, top diabetologists interviewed by PharmAsia News in India said they would take a more cautious approach on use of the drug until more research data is published